Pharmaceuticals company Marksans Pharma announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Operating revenue stood at Rs 641.9 crore, up by 20.8% YoY driven by strong performance across all key markets, led by US and followed by ANZ. Gross profit stood at Rs 383.5 crore, up by 37.7% YoY, with a gross margin expansion of 732 bps to 59.7%. Growth is attributed to continued softening of raw material prices and a better product mix. EBITDA stood at Rs 135.7 crore up by 19.1%, with a margin of 21.1%. EPS grew by 15.8% YoY to Rs 2.1. H1FY25 Financial Highlights: Operating revenue stood at Rs 1,232.5 crore, up by 19.5% YoY driven by growth across all key markets, new product launches and share gains with existing customers. US business grew by 33.5% YoY. UK & Europe grew by 8.5% YoY. Australia & New Zealand grew by 20.7% YoY. Gross profit came in at Rs 712.4 crore, up by 33.0% YoY, with a gross margin of 57.8%. EBITDA stood at Rs 264.1 crore, up by 22.3%, with an EBITDA margin of 21.4%. EPS grew by 21.7% YoY to Rs 4.1 Mark Saldanha, Managing Director, said: “Q2 marks a strong performance on back of a robust Q1. Growth trajectory improved further with revenue growth of 21% YoY. We are happy to share that this growth was broad based across all our key markets, led by the US market and also driven by increased market share. We continue to witness favourable raw material prices and improved product mix, thereby leading to a gross margin expansion of 732bps YoY and an all-time high quarterly EBITDA of Rs 135.7 crore. We anticipate stronger performance in the coming quarters due to our upcoming new launches, the onset of the winter season and scaling up of the TEVA facility.” Result PDF